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Multiple Potential Molecular Contributors to Atrial
Hypocontractility Caused by Atrial Tachycardia
Remodeling in Dogs
Reza Wakili, MD; Yung-Hsin Yeh, MD; Xiao Yan Qi, PhD; Maura Greiser, MD; Denis Chartier, BSc;
Kunihiro Nishida, MD, PhD; Ange Maguy, PhD; Louis-Robert Villeneuve, MSc; Peter Boknik, MD;
Niels Voigt, MD; Judith Krysiak, PhD; Stefan Ka¨a¨b, MD; Ursula Ravens, MD;
Wolfgang A. Linke, MD; Gerrit J.M. Stienen, MD; Yanfen Shi, MD; Jean-Claude Tardif, MD;
Ulrich Schotten, MD, PhD; Dobromir Dobrev, MD*; Stanley Nattel, MD*
Background—Atrial fibrillation impairs atrial contractility, inducing atrial stunning that promotes thromboembolic stroke.
Action potential (AP)-prolonging drugs are reported to normalize atrial hypocontractility caused by atrial tachycardia
remodeling (ATR). Here, we addressed the role of AP duration (APD) changes in ATR-induced hypocontractility.
Methods and Results—ATR (7-day tachypacing) decreased APD (perforated patch recording) by 50%, atrial contractility
(echocardiography, cardiomyocyte video edge detection), and [Ca2]i transients. ATR AP waveforms suppressed [Ca2]i
transients and cell shortening of control cardiomyocytes; whereas control AP waveforms improved [Ca2]i transients and cell
shortening in ATR cells. However, ATR cardiomyocytes clamped with the same control AP waveform had 60% smaller
[Ca2]i transients and cell shortening than control cells. We therefore sought additional mechanisms of contractile
impairment. Whole-cell voltage clamp revealed reduced ICaL; ICaL inhibition superimposed on ATR APs further suppressed
[Ca2]i transients in control cells. Confocal microscopy indicated ATR-impaired propagation of the Ca2 release signal to the
cell center in association with loss of t-tubular structures. Myofilament function studies in skinned permeabilized
cardiomyocytes showed altered Ca2 sensitivity and force redevelopment in ATR, possibly due to hypophosphorylation of
myosin-binding protein C and myosin light-chain protein 2a (immunoblot). Hypophosphorylation was related to multiple
phosphorylation system abnormalities where protein kinase A regulatory subunits were downregulated, whereas autophos-
phorylation and expression of Ca2-calmodulin-dependent protein kinase II and protein phosphatase 1 activity were
enhanced. Recovery of [Ca2]i transients and cell shortening occurred in parallel after ATR cessation.
Conclusions—Shortening of APD contributes to hypocontractility induced by 1-week ATR but accounts for it only
partially. Additional contractility-suppressing mechanisms include ICaL current reduction, impaired subcellular Ca2
signal transmission, and altered myofilament function associated with abnormal myosin and myosin-associated protein
phosphorylation. The complex mechanistic basis of the atrial hypocontractility associated with AF argues for upstream
therapeutic targeting rather than interventions directed toward specific downstream pathophysiological derangements. (Circ
Arrhythm Electrophysiol. 2010;3:530-541.)
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Atrial fibrillation (AF) contributes significantly to theoccurrence of stroke and other thromboembolic compli-
cations.1 Atrial hypocontractility promotes the formation of
left atrial thrombi that cause AF-related thromboembolic
events.1,2 AF-associated atrial tachycardia remodeling (ATR)
reduces action potential (AP) duration (APD), and APD-
Clinical Perspective on p 541
Received December 18, 2009; accepted July 15, 2010.
From the Department of Medicine and Research Center (R.W., Y.-H.Y., X.Y.Q., D.C., K.N., A.M., L.R.V., Y.S, J.C.T., S.N.), Montreal Heart Institute
and Universite´ de Montre´al, and Department of Pharmacology and Therapeutics (S.N.), McGill University, Montreal, Quebec, Canada; Department of
Pharmacology and Toxicology (R.W., N.V., U.R., D.D.), Dresden University of Technology, Dresden, Germany; Division of Experimental Cardiology
(N.V., D.D.), Department of Internal Medicine I, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany; Chang Gung Memorial
Hospital (Y.-H.Y.) and Chang Gung University, Tao-Yuan, Taiwan; Department of Physiology (G.J.M.S.), VU Medical Center, Amsterdam, The
Netherlands; Department of Pharmacology and Toxicology (P.B.), University of Mu¨nster, Mu¨nster, Germany; Department of Cardiovascular Physiology
(J.K., W.A.L.), Ruhr University, Bochum, Germany; Department of Medicine I (R.W., S.K.), Klinikum Grosshadern, Ludwig-Maximilians University,
Munich, Germany; and Department of Physiology (M.G., U.S.), University of Maastricht, Maastricht, The Netherlands.
*Drs Dobrev and Nattel share senior authorship.
The online-only Data Supplement is available at http:// circep.ahajournals.org/cgi/content/full/ CIRCEP.109.933036/DC1.
Correspondence to Stanley Nattel, MD, 5000 Belanger St E, Montre´al, Quebec H1T 1C8, Canada. E-mail stanley.nattel@icm-mhi.org
© 2010 American Heart Association, Inc.
Circ Arrhythm Electrophysiol is available at http://circep.ahajournals.org DOI: 10.1161/CIRCEP.109.933036
530
 at Vrije on July 11, 2011circep.ahajournals.orgDownloaded from 
prolonging drugs improve ATR-induced atrial hypocontrac-
tility.3 APD is an important determinant of cellular Ca2
loading and the systolic Ca2 transient that triggers contrac-
tion. ATR decreases atrial cardiomyocyte Ca2 transients,
contributing to impaired cellular contractile function.2 Re-
duced Ca2 transients have been related to decreased cellular
Ca2 entry resulting from L-type Ca2 current (ICaL) down-
regulation by ATR,2,4 but the marked APD shortening caused
by ATR could itself account for reduced Ca2 transients and
hypocontractility.3,5 Ca2-handling protein phosphorylation
changes also occur in AF.6 A recent study reported subcel-
lular Ca2-handling abnormalities in atrial hypocontractility
caused by chronic (over several months) AF.7 However,
short-term AF (over several days) can cause reversible atrial
mechanical dysfunction and thromboembolic complications,8
with apparent normalization by APD-prolonging drugs.3 This
study aimed to (1) evaluate the role of APD changes in
hypocontractility induced by 1-week ATR, (2) determine
whether APD changes alone were insufficient to account for
contraction abnormalities, and (3) assess in detail other
potential contributors.
Methods
This section includes essential methodologies. Additional details are
found in the online-only Data Supplement.
Animal Model
All animal care and handling procedures were in accordance with
National Institutes of Health guidelines (http://oacu.od.nih.gov/
training/index.htm) and were reviewed and approved by the Animals
Research Ethics Committee of The Montreal Heart Institute (Mon-
tre´al, Quebec). Sixty-three adult mongrel dogs (22 to 36 kg) were
divided into 2 groups: control (n35) and 1-week ATR (n28).
Under diazepam (0.25 mg/kg IV), ketamine (5.0 mg/kg IV), and
halothane (1% to 2%) anesthesia, unipolar leads were inserted into the
right ventricular apex and right atrial (RA) appendage and connected to
pacemakers in the neck. Atrioventricular block was created by radio-
frequency ablation, and the right ventricle pacemaker was programmed
to 80 bpm. After 24-hour recovery, the atrial pacemaker was pro-
grammed to pace the RA appendage at 400 bpm for 7 days.
On study days, dogs were anesthetized with morphine (2 mg/kg
SC) and -chloralose (120 mg/kg IV load at 29.25 mg/kg per hour)
and ventilated mechanically. RA appendage effective refractory
periods (AERPs) were determined with 8 basic stimuli followed by
1 premature stimulus (5-millisecond [ms] decrements). AF was
induced multiple times by burst pacing to determine AF duration in
each dog, and mean AF duration was calculated using average
individual dog AF duration values.
Transthoracic echocardiography was performed under sedation
(acepromazine 0.07 mg/kg and buprenorphine 0.009 mg/kg IM) in
sinus rhythm. An average of 3 to 6 cardiac cycles was used, with the
operator blinded to treatment assignment.
After open chest studies, hearts were excised through a median
thoracotomy and immersed in oxygenated Tyrode solution. RA
tissue was frozen in liquid N2 for molecular biology. For cellular
studies, RA preparations were coronary perfused at 10 mL/min for
cardiomyocyte isolation. After perfusion with Ca2-free Tyrode-
containing collagenase (110 U/mL) and 0.1% bovine serum albumin
for 40 minutes, single cells were obtained by trituration. Cell
capacitance averaged 1024 picofarads and 1015 picofarads in
control and ATR cells, respectively.
Cellular Studies
Isolated cardiomyocytes were field stimulated through 10-ms
1.5threshold square-wave pulses at a temperature of 35°C. Cell
shortening, maximum contracting (L/t), and relaxing (L/t)
slopes of cell shortening were measured by video edge detection
based on the average of 10 consecutive beats. Cell shortening was
measured during field stimulation with a video edge detector, with
edge detection cursors positioned at both cell ends to measure
whole-cell shortening. When AP clamp waveforms were applied
through a patch pipette, absolute cell shortening was measured at
only 1 cell end.
Cellular [Ca2]i transients were recorded with Indo-1 AM. Cells
were excited with a 340-nm wavelength ultraviolet light. Emission
ratios (400/500 nm) were used to calculate [Ca2]i. Isolated cardio-
myocytes from additional control and ATR dogs also were studied
by confocal microscopy to analyze subcellular Ca2 transient prop-
erties with Fluo-4 acetoxymethyl ester. For mean data analysis, 5
consecutive beats of each region of interest were averaged per cell
and afterward per dog, allowing a comparison of lateral (longitudinal
scans) or subsarcolemmal (transverse scans) to central Ca2 tran-
sient amplitudes. Fluorescence intensity values were normalized to
end-diastolic fluorescence intensity in regions of interest.
AP recordings were performed with whole-cell perforated patch
techniques and current-clamp mode. Pipette tips were filled with
nystatin-free intracellular solution by capillary action, and pipettes
then were back filled with nystatin-containing (600 g/mL) pipette
solution. Whole-cell voltage clamp was performed with tight seal
methods. Tip resistances were between 3 and 5 M. Junction
potentials averaged 15.9 mV and were corrected for AP recordings
only. All recordings were performed at 350.5°C. In some experi-
ments, mean control or ATR AP waveforms were applied as
voltage-clamp command signals while recording Ca2 transients
or cell shortening. RA cardiomyocytes were subjected to typical
AP waveforms from control and ATR cardiomyocytes at 2 Hz for
sequential 6-minute periods (in randomized order). Parallel Ca2
transients (10 to 20 beats) were recorded in 120-second intervals.
For analysis, all Ca2 transients obtained during the 6-minute
periods were averaged and the meanSEM calculated within
each AP waveform group. For solution contents, see the online
supplement.
Transverse Tubule Network Analysis
Freshly isolated atrial cells were plated on laminin-coated Petri
dishes. Cells were labeled with 2-mol/L di-4-ANEPPS in Tyrode
solution. Samples were excited with an argon (488-nm) laser, and
emitted fluorescence over 515-nm Z-series (250 nm) was acquired
with an LSM 710 confocal microscope. The calculated point spread
function of the imaging system was obtained with the use of 170-nm
fluorescent latex beads. Acquired Z-series were deconvolved using
maximum likelihood estimation with a Richardson-Lucy algorithm
following gaussian prefiltering implemented with Huygens Profes-
sional 3.5.0. Projections were analyzed by excluding the cell mem-
brane and quantifying intracellular membrane staining. Transverse
tubule (t-tubule) density was estimated from the pixel intensity
normalized to the surface area of the intracellular region for each
cardiomyocyte.
Skinned Cardiomyocyte Studies
Cardiomyocytes were mechanically isolated, permeabilized, and
mounted. Isometric force measurements were performed at 15°C and
resting sarcomere length of 2.2 m. Force redevelopment rate (KTR)
was determined during activation at different Ca2 concentrations.
Force redevelopment after restretch was fitted by a single exponen-
tial function (Marquart-Levenberg algorithm) to estimate KTR. Pas-
sive force was determined in relaxing solution by applying the same
shortening (20% of original cell length) followed by a restretch after
10 seconds.
Protein Studies
RA tissue homogenates were prepared from freeze-dried tissue,
and protein concentrations were determined with Amido-black
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10B. Proteins were fractionated on SDS-PAGE and transferred to
nitrocellulose membranes. Protein expression was quantified as
previously described.6 For details regarding antibodies, dilution,
and source, see the online supplement. Serine and threonine
protein phosphatase activity were assessed with phosphorylase-A
as substrate and quantified as nanomoles of 32Pi released/mg
protein per minute. Differentiation between type 1 and type 2A
protein phosphatase (PP1 and PP2A, respectively) activities was
obtained with okadaic acid (3 nmol/L). Protein bands were
visualized with electrochemoluminescence reagents and
Hyperfilm-ECL. The films were evaluated densitometrically with
Phoretix 1D software. Myosin heavy chain (MHC) isoform
composition was analyzed by 1D SDS-PAGE. The separating gel
contained 12% total acrylamide (acrylamide-to-bis-acrylamide
ratio, 200:1; pH 9.3), whereas the stacking gel contained 3.5%
total acrylamide (acrylamide-to-bis-acrylamide ratio, 20:1; pH
6.8). Gels were silver stained and analyzed by laser densitometry.
To check for linearity, different amounts of protein were loaded
on the gels, and band densities were determined. Only samples
within the linear range (typically 0.2 to 1.0 g of total protein)
were used in the evaluation. Agarose-strengthened 2% SDS-
PAGE was used to detect titin.
Data Analysis
Skinned cardiomyocyte force-pCa relations were fit with the use
of a nonlinear procedure by the Hill equation: F(Ca2)/
Fmax[Ca2]nH/(Ca50nH[Ca2]nH), where F denotes the steady-
state force; Fmax, active isometric force at saturating Ca2 concen-
trations (Marquart-Levenberg algorithm); and nH, Hill coefficient,
indicating steepness of the force-pCa relation.
All data are presented as meanSEM. For single comparisons,
paired or nonpaired t tests were applied as appropriate. Repeated-
measures analyses were performed with 2-way ANOVA. When
significant interactions were found between main effects,
Bonferroni-corrected t tests were applied to determine the levels of
the repeated measures at which significant differences occurred (the
P values shown were obtained by multiplying each P by the number
of repeated tests performed). In the absence of interaction, the
significance of main effects differences is shown. Analyses of
nonrepeated measurements in multiple groups (control versus 24-
hour recovery versus 48-hour recovery) were performed by 1-way
ANOVA followed (if significant) by the least significant difference
test. The specific statistical test applied for each analysis is provided
in the online supplement. A 2-tailed P	0.05 was considered statis-
tically significant.
The authors had full access to the data and take responsibility for
its integrity. All authors have read and agree to the manuscript as
written.
Results
In Vivo Experiments
All ATR dogs showed atrial remodeling, with significantly
reduced AERPs and AERP rate adaptation (Table 1). Arterial
pressures, left ventricular (LV) end-diastolic pressure, and
RA pressure were unchanged by ATR. ATR significantly
increased the duration of burst pacing-induced AF, an index
of the AF-maintaining substrate, by 10-fold (P	0.001).
Echocardiography revealed atrial contractile dysfunction in
ATR (Figure 1A and B). Overall, atrial fractional area and
Figure 1. A, Representative M-mode
echocardiographic images showing the
left atrial (LA) dimension at end-systole
and diastole. B, Pulsed-wave Doppler
recording at the mitral valve, with E- and
A-waves shown. Circles indicate
P-waves preceding active atrial contrac-
tion. C to E, MeanSEM echocardio-
graphic results of atrial fractional short-
ening of LA area and LA diameter (C),
mitral valve velocities at E- and A-wave
(D), and E/A ratio (E) in control and ATR
dogs (n8 for both groups). CTL indi-
cates control; Dias, diastole; Sys,
systole. *P	0.05.
Table 1. In Vivo Hemodynamic and Electrophysiological Data
Control (n16) ATR (n16)
Systolic BP, mm Hg 1325 1283
Diastolic BP, mm Hg 824 802
LVEDP, mm Hg 4.90.5 4.50.4
RAP, mm Hg 2.70.5 2.60.4
AERP (BCL 360 ms), ms 1265 703*
AERP (BCL 300 ms), ms 1234 682*
AERP (BCL 250 ms), ms 1184 683*
AERP (BCL 200 ms), ms 1134 703*
AERP (BCL 150 ms), ms 1024 702*
DAF, s 266 32456†
Data are presented as meanSEM. BCL indicates basic cycle length; BP,
blood pressure; DAF, duration of AF; LVEDP, LV end-diastolic pressure; RAP, RA
mean pressure.
*P	0.001 versus control.
†P	0.01 versus control.
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diameter shortening were decreased by 14% (P	0.05) and
26% (P	0.05), respectively (Figure 1C). Mitral valve
A-wave velocity (representing active atrial contractile func-
tion) was decreased by45% in ATR (P	0.05) (Figure 1D),
whereas E-wave velocity (representing passive atrial empty-
ing function) was unchanged. The E/A ratio was nearly
doubled by ATR (2.70.2) versus control (1.60.2; P	0.05)
(Figure 1E). LV dimensions and ejection fraction were
unchanged (Table 2).
Cell Shortening, Ca2 Transients, and APD
Figure 2A shows representative cell shortening recordings at
1 Hz. Overall cell shortening was strongly reduced by 85%
(P	0.001) in ATR cardiomyocytes versus control cells
(Figure 2B). ATR decreased cell shortening over a wide
range of frequencies (P	0.001) (supplemental Figure 1).
Absolute cell shortening and relaxation rates were substan-
tially reduced in ATR (L/t and L/t by 81% and
93%, respectively; P	0.001 for each) (Figure 2C).
Figure 2D shows representative steady-state Ca2 transient
recordings. ATR decreased Ca2 transient amplitudes over a
wide range of frequencies, flattening Ca2 transient fre-
quency dependence (Figure 2E). Diastolic [Ca2]i levels were
unchanged (supplemental Figure 2). To assess sarcoplasmic
reticulum (SR) Ca2 content, we measured caffeine-evoked
Ca2 transients as illustrated in Figure 3A. Overall data
(Figure 3B) show 30% decreases (P	0.05) in caffeine-
evoked Ca2 transients in ATR. Ca2 transient decay was
accelerated (time constant, 78240 ms) versus control
(132563 ms; P	0.01), suggesting increased forward mode
Na, Ca2 exchange function (Figure 3C). These results
point to reduced SR-derived Ca2 transients associated with
reduced SR Ca2 stores as a basis for hypocontractility,
consistent with prior observations.2
We then recorded AP waveforms. Ca2 entry occurs
predominantly during the AP plateau where changed plateau
voltages and durations affect SR Ca2 loading9 and could
explain ATR-induced hypocontractility.3 Figure 3D shows
representative AP recordings. ATR abbreviated APD over a
wide range of frequencies by 50% overall (P	0.001)
(Figure 3E).
Contribution of AP Waveform Changes to
Reduced Ca2 Transients
Mean AP waveforms obtained in control and ATR cells at 2
Hz were applied to individual control cells at 2 Hz during
Ca2 transient or cell shortening recording. Representative
Ca2 transients in 1 control cell are shown in Figure 4A. The
ATR waveform clearly reduced Ca2 transients. Overall,
clamping control cells with ATR APs caused a 45%
decrease (P	0.05) in Ca2 transient amplitude (Figure 4B).
We then used the same approach to study the impact of APD
abbreviation on cell shortening in AP-clamped control cells.
The ATR AP waveform also substantially reduced cell
shortening (Figure 4C, left) by 75% overall (P	0.001)
(Figure 4C, right).
If the AP waveform changes induced by ATR are the sole
cause of cell Ca2 and contractile abnormalities, it should be
possible to normalize Ca2 transients and cell shortening by
applying control waveforms to ATR cells. Ca2 transient
recordings from an ATR cell exposed to control and ATR
waveforms are shown in Figure 4D. The control AP wave-
form improved the Ca2 transient; overall, Ca2 transient
amplitudes were approximately doubled (P	0.05) in ATR
cells when control waveforms were applied (Figure 4E).
Nevertheless, comparing the recordings in Figure 4D with
control cell recordings in Figure 4A and mean data in Figure
Figure 2. A, Representative recordings
of cell shortening during 1-Hz field
stimulation from single CTL and ATR
cardiomyocytes. B, Corresponding
meanSEM data (n13 and n17 cells
for CTL and ATR, respectively).
***P	0.001 for CTL versus ATR. C,
MeanSEM cell shortening kinetics
(L/t for contraction and L/t
relaxation) at 1-Hz stimulation in CTL
versus ATR cardiomyocytes (n13 and
n17 for CTL and ATR, respectively).
***P	0.001. D, Original recordings of
Ca2 transients during 0.5-Hz stimula-
tion. E, MeanSEM Ca2 transient
amplitude as function of stimulation fre-
quency (n25 and 15 cells for CTL and
ATR, respectively). ***P	0.001 for effect
of group. CTL indicates control.
Table 2. Echocardiographic LV Data
Control (n5) ATR (n7)
LVVd, mL 42.96.4 46.73.0
LVVs, mL 17.84.1 19.32.2
EF, % 60.03.6 58.93.2
Data are presented as meanSEM. There were no statistically significant
intergroup differences. EF indicates ejection fraction; LVVd, left ventricular
volume diastolic; LVVs, LV volume systolic.
Wakili et al Atrial Hypocontractility Due to Atrial Tachycardia 533
 at Vrije on July 11, 2011circep.ahajournals.orgDownloaded from 
4E with control cell data in Figure 4B, the control AP
waveform did not normalize Ca2 transients in ATR cells.
For example, Ca2 transient amplitudes in control cells
clamped with a control AP waveform averaged 14733
nmol/L, whereas ATR cells clamped with the same waveform
had Ca2 transient amplitudes of 615 nmol/L (P	0.05).
Similar results were obtained for contractility changes. The
control AP waveform significantly improved contractility in
ATR cells (Figure 4F) but clearly did not return cell short-
ening to control (compare to Figure 4C); control cell short-
ening averaged 5.91.0 m with the control AP waveform
versus 2.40.3 m in ATR cells clamped with the control
AP waveform (P	0.01). These results confirm a role of
ATR-induced AP waveform changes in Ca2 release and
contractile abnormalities but indicate that only a minority of
the changes are attributable to APD abbreviation. We there-
fore examined additional potential contributors to ATR-
induced Ca2 transient reduction and hypocontractility.
Figure 3. A, Examples of caffeine-
induced Ca2 transients in CTL and ATR
cardiomyocytes. A 10-mmol/L local caf-
feine concentration was achieved in
	500 ms with a laminar flow rapid solu-
tion switching system. B, MeanSEM
caffeine-evoked Ca2 transient ampli-
tudes (n17 and n23 cells for CTL
and ATR, respectively). *P	0.05. C,
MeanSEM Ca2 decay time constant
(tau) of caffeine-induced Ca2 transients
(n17 and n23 cells for CTL and ATR,
respectively). **P	0.01. D, Examples of
AP waveforms obtained at 1-Hz stimula-
tion. E, MeanSEM APD90 at different
pacing frequencies (n12 and 10 cells
for CTL and ATR, respectively).
***P	0.001 for CTL versus ATR, effect of
group. F, MeanSEM ICaL density as a
function of test potential (n11 cells for
each group). **P	0.01. APD90 indicates
APD at 90%; TP indicates test potential.
Figure 4. AP clamp results (all data obtained with mean AP waveforms obtained in current-clamp mode at 2 Hz and applied to other
cells in voltage-clamp mode at 2 Hz). A, Ca2 transient recordings obtained from a single CTL cell during application of typical CTL
(black) or ATR (red) AP-waveform. B, MeanSEM diastolic Ca2 levels and Ca2 transient amplitudes obtained with AP clamp in CTL
cells (n5). *P	0.05 for CTL AP versus ATR AP. C, Cell-shortening elicited by AP clamp in CTL (left, original cell shortening recordings
from a single CTL cell subjected to typical CTL [black] or ATR [red] AP waveforms; right, meanSEM cell shortening during AP clamp
in CTL cells) (n8). ***P	0.001 for ATR AP versus CTL AP. D, Ca2 transient recordings obtained from a single ATR cell during appli-
cation of typical CTL (red) or ATR (black) AP waveforms. E, MeanSEM diastolic Ca2 levels and Ca2 transient amplitudes obtained
with AP clamp in ATR cells (n7). *P	0.05 for CTL AP versus ATR AP. F, Cell shortening elicited by AP clamp in ATR (left, original cell
shortening recording from a single ATR cell subjected to typical CTL [red] or ATR [black] AP waveforms; right, meanSEM cell shorten-
ing during AP clamp in ATR cells) (n7). ***P	0.001 for ATR AP versus CTL AP. CTL indicates control.
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ICaL Changes
Previous studies have shown important ICaL downregulation
in ATR,4,10,11 and ICaL is the major source of Ca2 entry for
SR Ca2 loading.9 For a given AP waveform, decreased ICaL
channel function would be expected to diminish cellular Ca2
loading by virtue of reduced Ca2 entry through the L-type
channel. Figure 3F shows mean ICaL density-voltage relations
in ATR and control cells obtained with 10 mmol/L EGTA-
containing pipettes. ICaL was significantly reduced (68%;
P	0.01 at all test potentials between 10 and 40 mV) in
ATR cells, consistent with previous results.4,10,11 ICaL kinetics
and voltage dependence were unchanged (supplemental Fig-
ure 3). These data may not accurately reflect physiological
ICaL changes because reduced Ca2 transients in ATR cells
should decrease [Ca2]i-dependent ICaL inactivation, which
would not be reflected in 10-mmol/L EGTA-buffered cells.
We therefore repeated the ICaL measurements with EGTA-
free pipette solution. Supplemental Figure 4A shows repre-
sentative ICaL recordings, and Figure 4B shows corresponding
current density-voltage relations. Overall, peak ICaL den-
sity was reduced by 63% in ATR cells (P	0.001 at all test
potentials between 10 and 40 mV). In contrast to
findings with EGTA-containing pipettes, fast inactivation
time constants were significantly slowed (P	0.001) (sup-
plemental Figure 5A), consistent with reduced Ca2-
dependent ICaL inactivation. Slow ICaL inactivation kinetics
(supplemental Figure 5B) and ICaL voltage dependence
(supplemental Figure 5C) were unaltered by ATR under
EGTA-free conditions, but recovery was accelerated
(P	0.01) (supplemental Figure 5D).
To assess whether decreased Ca2 entry through ICaL
reduces Ca2 transients over and above the APD abbreviation
caused by ATR, we recorded Ca2 transients in control cells
subjected to AP clamping with control APs, ATR APs, and
then ATR APs in the presence of 5 mol/L nifedipine. Figure
5A shows representative Ca2 transients. ATR APs reduced
Ca2 transients versus control APs, but when nifedipine was
added to suppress Ca2 current, Ca2 transients were further
decreased for the same ATR APs. The top left shows
corresponding cell shortening. Cell contraction changes par-
alleled those in Ca2 transients. Mean Ca2 transient data
(Figure 5B) indicate that decreasing ICaL significantly reduces
Ca2 transients over and above changes produced by ATR
AP alterations (P	0.05).
Expression and Phosphorylation of Key
Ca2-Handling Proteins
To uncover potential contributions of altered Ca2-handling
protein expression to Ca2-handling abnormalities, we per-
formed Western blots with specific antibodies directed
against total and phosphorylated forms of target proteins. We
found no significant differences between ATR and control
atria in SR-associated proteins (supplemental Figure 6).
Expression levels of total ryanodine receptor 2 (RyR2),
protein kinase A (PKA)-phosphorylated RyR2 (at Ser2809),
Ca2-calmodulin-activated protein kinase (CaMKII)-phos-
phorylated RyR2 (at Ser2815), and fractional RyR2-phos-
phorylation states (ratios of Ser2809-RyR2 and Ser2815-
RyR2 to total RyR2) were similar in control and ATR cells
(supplemental Figure 6A). Calsequestrin-2, the major SR
Ca2 buffer system protein, was similarly unaffected by
ATR, as were SR Ca2 ATPase and Na,Ca2 exchange 1
(supplemental Figure 6B). No significant changes were noted
for total phospholamban (PLB) or for PKA-phosphorylated
(at Ser16) or CaMKII-phosphorylated (at Thr17) PLB.
Subcellular Ca2 Handling
Recent studies have emphasized the importance of subcellu-
lar Ca2-handling abnormalities in rabbits with ATR12 and
sheep with long-standing AF or heart failure.7,13 We assessed
this possibility in control and ATR cardiomyocytes with the
use of confocal microscopy. Longitudinal line scans showed
no significant change in cells from ATR dogs compared with
controls (supplemental Figure 7). Ca2 transient signals were
reduced in ATR cells but uniformly along the length of the
cell. In contrast, transverse line scans showed substantial
alterations (Figure 6). Whereas under control conditions,
subsarcolemmal and central cellular Ca2 signals were sim-
ilar (Figure 6A), in ATR cells, central Ca2 transients were
delayed and reduced in amplitude compared to subsarcolem-
mal signals (P	0.001), indicating impaired Ca2 signal
Figure 5. AP-clamp experiments to study role of
ICaL changes independent of APD. All data were
obtained with mean AP waveforms based on all
current-clamp recordings at 2 Hz. A, Top left
shows mean CTL AP waveform (black) and ATR
AP waveform (green) applied in voltage-clamp
mode at 2 Hz. The bottom shows Ca2 transient
recordings obtained from a single CTL cell during
application of typical CTL (black) or ATR (purple)
AP waveform and during ATR AP waveform and
perfusion with 5-mol/L nifedipine (red). The top
left shows corresponding cell shortening record-
ings from a CTL cell subjected to CTL (black) or
ATR (purple) AP waveforms and during ATR AP
waveform and perfusion with nifedipine (red). B,
MeanSEM Ca2transient amplitudes obtained
with AP clamp in CTL cells (n4). *P	0.05 for
ATR APnifedipine versus ATR AP alone. CTL
indicates control; Nif, nifedipine.
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propagation toward the center of the cell (Figure 6B).
Confocal imaging with di-4-ANEPPS indicated the presence
of t-tubular structures under control conditions, which were
greatly reduced in ATR cells (supplemental Figure 8A).
Overall, t-tubule density was decreased by 60% in ATR
(P	0.01) (supplemental Figure 8B).
Force Development in
Permeabilized Cardiomyocytes
To investigate whether abnormal myofibrillar behavior may
contribute to atrial contractile dysfunction, we assessed myo-
filament mechanics by recording force development in
skinned permeabilized cardiomyocytes (Figure 7A). Passive
and active force development and KTR were measured in 18
cardiomyocytes from 5 ATR dogs and 19 cardiomyocytes
from 5 control dogs. Figure 7B shows a recording of
isometric force development in an ATR cardiomyocyte at
saturating Ca2 (pCa 4.5). Overall data are presented in
Figure 7C. Passive force per cross-sectional area were not
different in ATR (1.690.17 kN/m2) versus control cells
(1.940.33 kN/m2; PNS). Maximal Ca2-activated iso-
metric force per cross-sectional area also were comparable
(ATR, 27.711.75 kN/m2; control, 31.653.49 kN/m2;
PNS). Average force-pCa relationships are shown in Figure
7D. The pCa50 values were slightly, but significantly, higher
in ATR (5.490.01) versus control (5.460.02; P	0.001),
indicating increased Ca2 responsiveness in ATR. The steep-
ness of the force-pCa relation (nH) was not different (ATR,
3.940.16; control, 4.240.27). The KTR (measured at pCa
4.5) was significantly slower (by 20%) in ATR (3.740.30
seconds1) versus control (4.720.30 seconds1; P	0.05),
suggesting altered cross-bridge kinetics (Figure 7D, right).
Expression and Phosphorylation of Key
Myofilament Proteins
We analyzed expression changes in important myofilament
proteins as a potential contributor to contractile abnormali-
ties. Expression levels of thin myofilament proteins troponin
(Tn)I and TnC are shown in Figure 8A. Total TnI expression,
PKA-phosphorylated (at Ser23/24) TnI, the phosphorylated/
total TnI ratio, and total TnC were unchanged by ATR. Thick
myofilament and myosin-related protein results are presented
in Figure 8B. Total protein levels of thick myofilament
myosin-binding protein-C (MyBP-C) were unchanged. How-
ever, PKA-phosphorylated MyBP-C (at Ser282) was signifi-
cantly decreased in ATR by 35% (P	0.05), resulting in a
decreased Ser282-MyBP-C/total MyBP-C ratio (P	0.05).
Reduced MyBP-C phosphorylation could contribute to alter-
ations in cross-bridge kinetics. Myosin light chain (MLC)
kinase phosphorylation of MLC protein-2a (MLC2a) at
Ser21/22 is suggested to improve atrial contractility by
improving cross-bridge cycling kinetics,14 and we found a
30% reduction in MLC2a phosphorylation in ATR
(P	0.05) (Figure 8B). Contractile protein composition was
determined by 1D SDS-PAGE (supplemental Figure 9). The
detail of the MHC region shown in Figure 8C illustrates the
presence of 2 MHC-isoforms, fast () and slow (), in atrial
tissue. The quantity of -MHC as a percentage of total ()
MHC content was not affected by ATR. The expression of
titin, a giant protein that acts as a molecular spring in the
I-band, is anchored at the Z-disk, and is expressed in 2 main
cardiac isoforms (a longer, more-compliant N2BA titin
[3.3 to 3.5 MDa] and a shorter, stiffer N2B titin [3.0 MDa])
was unchanged in ATR (Figure 8D). Overall, the myofil-
ament analyses point to dephosphorylation of MyBP-C and
MLC2a as potential contributors to ATR-induced myofil-
ament dysfunction.
Phosphorylation Changes, Kinases,
and Phosphatases
To identify potential sources of altered myofilament protein
phosphorylation, we analyzed the expression of PP1 and
PP2A and of PKA and CaMKII (supplemental Figure 10). In
Figure 6. Transverse distribution of Ca2
fluorescence in CTL and ATR cells. A,
CTL group results. An image illustrating
the scan direction is shown along with
the corresponding line scan image (stim-
ulation frequency, 1 Hz) and a smaller
image showing regions of interest (cen-
tral and SSL) with corresponding original
Ca2 transient recordings. Also shown,
CTL group meanSEM data for
SSL versus central Ca2 transients.
B, ATR group results and ATR group
meanSEM data (n5 dogs/group).
***P	0.001 for SSL versus central Ca2
transients. CTL indicates control; SSL,
subsarcolemmal.
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addition, we directly measured PP enzyme activity. Total
(PP1PP2A) and PP2A-related activities were comparable in
both groups, whereas PP1 activity was 28% greater in ATR
(P	0.05) (supplemental Figure 10A). The increased PP1
activity was not attributable to expression differences (sup-
plemental Figure 10B). PKA expression was unchanged for
PKAc (the catalytic subunit), whereas the regulatory subunit
PKAII was decreased by 33% (P	0.05) (supplemental
Figure 10C). ATR increased the expression and autophos-
phorylation of the cytosolic CaMKII isoform by 78% and
123%, respectively (P	0.05 for each), whereas the ratio of
autophosphorylated CaMKII to total CaMKII was un-
changed (PNS) (Figure 8D). The increase in PP1 activity
and decrease in PKAII protein expression, consistent with
previous data,6,15 potentially account for the observed myo-
filament protein dephosphorylation. Increased PP1 activity
may have offset the increased expression of the cytosolic
CaMKII isoform, explaining the lack of changes in CaMKII
phosphorylation of investigated proteins.
Recovery of ATR-Induced Electrophysiological
and Contractile Alterations
To analyze the relationship between electric and contractile
changes during ATR recovery, we studied dogs (5 per group)
subjected to 7-day ATR followed by a 24- or 48-hour
nonpaced recovery interval as well as 5 concurrent controls.
The results are summarized in Table 3. After 24-hour recov-
ery, significant decreases remained for APDs recorded over a
wide range of frequencies (P	0.01) (supplemental Figure
11A), Ca2 transients (P	0.01) (supplemental Figure 11B),
and cell-shortening (P	0.001) (supplemental Figure 11C). In
contrast, full recovery was seen for all indices at 48 hours
(PNS versus control).
Discussion
In the present study, we observed that 7 days of ATR are
sufficient to substantially impair atrial contractile function. A
significant part of the contractile abnormality can be attrib-
uted to AP changes caused by ATR, but even when these are
Figure 7. A, Images of a single perme-
abilized cardiomyocyte from a CTL and
an ATR dog mounted in the experimen-
tal setup between force transducer and
piezoelectric motor. B, Example of force
recording. Contraction-relaxation
sequence recorded from a cardiomyo-
cyte at maximally activating Ca2 con-
centration (pCa 4.5). Slack test used to
determine the KTR. C, Passive force at
pCa 9.0 and maximum force pCa 4.5
expressed per cross-sectional area in
both groups. D, Isometric force as a
function of the pCa of the activating
solution, normalized to the force at satu-
rating Ca2 concentration and maximum
KTR in CTL and ATR. *P	0.05 versus
CTL. CTL indicates control.
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accounted for, substantial abnormalities in atrial Ca2 release
and contractility remain. Detailed analyses point to loss of
ICaL as a significant additional contributor along with poten-
tial roles for disturbed subcellular distribution of Ca2 release
and intrinsic myofilament dysfunction likely caused by my-
osin and myosin-associated protein dephosphorylation.
Previous Studies of Atrial
Hypocontractility Mechanisms
It has long been recognized that AF causes atrial hypocon-
tractility,16 and the role of atrial contractile dysfunction in the
thromboembolic complications of AF is well appreciated.8
Even very short-term AF (5 to 15 minutes) can cause
contractile dysfunction, but normal contraction resumes
within minutes of rhythm reversion after such brief episodes,
whereas persistent hypocontractility (lasting 24 hours) fol-
lows AF episodes lasting days to weeks.8 Atrial tachypaced
dogs with uncontrolled ventricular responses show an atrial
cardiomyopathic phenotype, with contractile dysfunction re-
lated to reduced Ca2 transients of uncharacterized mecha-
nism.2 In atrial tissue samples from patients with AF, con-
tractile force is impaired and can be normalized by increasing
extracellular Ca2 but not by exposure to a Ca2 channel
agonist, again suggesting a primary role for reduced Ca2
load.5
Several recent studies have addressed the mechanisms of
Ca2 transient abnormalities associated with atrial pathology.
Lenaerts et al7 reported detailed studies in sheep with long-
standing AF (average 
4 months) and ventricular dysfunc-
tion. Like us, they observed striking APD abbreviations and
reduced Ca2 transients. ICaL was diminished, but the reduc-
tion was limited when EGTA was omitted from the pipette.
They also noted increased Na, Ca2 exchange function and
expression and emphasized the importance of reduced
subsarcolemmal-RyR coupling efficiency along with loss of
t-tubules. They did not examine the role of APD changes or
Figure 8. Protein expression data (meanSEM
band intensities normalized to GAPDH and
expressed relative to CTL) and corresponding illus-
trative examples (right). A, TnI, Ser23/24 TnI-P,
and TnC with corresponding GAPDH bands (CTL,
n10; ATR, n8 atria/analysis). B, Total MyBP-C,
Ser282 MyBP-C-P, and PKA MLC2a-P with corre-
sponding GAPDH bands (CTL, n14; ATR, n10
atria/analysis). *P	0.05 versus CTL. C, MHC iso-
form composition (meanSEM values for  MHC
expression as a percentage of total () MHC
expression) and detail of the MHC region of an
SDS-PAGE illustrating the similarity in MHC
expression in the 2 groups (right). D, Titin N2BA
and N2B isoforms separated by 2% SDS-PAGE
(N2BA:N2B ratio meanSEM; n10 atria/group
per analysis; PNS ATR versus CTL). CTL indi-
cates control; MLC2a-P, phosphorylated MLC2a;
MyBP-C-P, phosphorylated MyBP-C; T2, titin deg-
radation band; TnI-P, phosphorylated TnI.
Table 3. Data Following ATR Recovery Versus Parallel
Control Dogs
Control
(n5)
ATR Recovery
24 h (n5)
ATR Recovery
48 h (n5)
APD90 at 1 Hz, ms 22014 16312* 20711
Ca2i transient, nM 19210 13112† 18311
Cell shortening, % 11.20.3 5.90.8‡ 9.60.8
All data were recorded at 1 Hz and shown as meanSEM. APD90 indicates
APD at 90%.
*P	0.05 versus control.
†P	0.01 versus control.
‡P	0.001 versus control.
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intrinsic contractile properties. Dibb et al13 characterized
Ca2 release properties in sheep with ventricular
tachypacing-induced heart failure. They noted substantial loss
of t-tubules associated with impaired centripetal propagation
of the Ca2 signal from the subsarcolemma to the center of
the cell. However, in rabbit atrial myocytes, ATR suppresses
centripetal Ca2 wave propagation despite a lack of t-tubules,
pointing to mechanisms other than reduced t-tubular
density.12
Several studies have suggested a prime role of atrial APD
abbreviation in AF-related contractile dysfunction. Atrial
contractility decreases rapidly in goats with electrically main-
tained AF, with a similar time-course to AERP abbrevia-
tion.17 Administration of the K channel blocker AVE0118
increases AERP and atrial contractility in contrast to absent
or limited effects of other positive inotropic agents like
digoxin, dobutamine, the Ca2 sensitizer EMD57033, and the
Ca2 channel agonist BayY5959.3 Similar effects of
AVE0118 have been observed in RA trabeculae of patients
with AF.18 On the basis of this evidence, the use of APD-
prolonging agents has been advocated to abrogate atrial
hypocontractility in AF.3
MyBP-C dephosphorylation has been noted in atrial tissue
samples from patients with AF.6 No previous studies have
noted changes in the expression and phosphorylation of
MLC2a, an important regulator of cardiac contraction.19 Eiras
et al20 described decreased force redevelopment in skinned
muscle fibers from patients with dilated atria in both sinus
rhythm and AF along with increased expression of  MHC
protein, TnT, and desmin in patients with AF only. Most
patients with AF had significant valvular heart disease (unlike
the control, sinus rhythm, and dilated atria groups), which can
markedly alter atrial function and gene expression.21
We noted changes in contractile protein (MyBP-C and
MLC2a) phosphorylation that likely contributed to contractile
abnormalities and addressed potential underlying mecha-
nisms by studying changes in key phosphorylation (kinase)
and dephosphorylation (phosphatase) systems. Consistent
with previous data in patients with chronic AF and goats with
sustained AF,6,15 global PP1 activity was increased in ATR,
whereas protein expression of the regulatory PKAII subunit
(which coordinates targeting of the PKAc subunits to PKA
targets) was reduced. Although we did not directly measure
PP1 and PKA activities in the myofilament and SR compart-
ments, greater local PP1, reduced PKA, or both activity likely
underlies hypophosphorylation (and resulting dysfunction) of
the 2 key cross-bridge cycling regulatory proteins MyBP-C
and MLC2a at established PKA sites. PKA phosphorylation
of RyR2 and PLB (Ser2809 and Ser16 sites, respectively) was
preserved in ATR despite increased PP1 activity and reduced
PKAII expression. In patients with chronic AF, SR-related
PP1 function is reduced because of increased inhibitor 1
activity,6 which controls PP1 activity exclusively at the SR,
specifically targeting phosphorylation of PLB and RyR2 at
Ser16 and Ser2815 sites, respectively.22,23 Thus, reduced PP1
activity in the SR compartment of ATR dogs may offset
reductions in PKAII expression at Ser16. On the other hand,
although higher global activity of CaMKII in the face of
reduced SR-related PP1 activity in ATR would be expected to
increase phosphorylation at CaMKII phosphorylation sites of
RyR2 and PLB (Ser2815 and Thr17, respectively), steady-
state phosphorylation at these sites was unchanged. Further
work clearly is needed to explain more fully SR PKA and
CaMKII phosphorylation properties in ATR.
Novel Elements and Potential Significance
Atrial contractile remodeling has important clinical conse-
quences, including increased atrial thrombogenesis and stroke
risk in patients with AF.24–26 Elucidating the underlying
pathophysiological mechanisms may allow for the identifica-
tion of new therapeutic targets. Whereas atrial contractility
changes have been attributed previously to APD reduction
based on indirect evidence,3,15,17,18 our study is the first to our
knowledge to examine directly the role of ATR-induced AP
waveform alterations. By applying AP waveforms from
control and ATR cardiomyocytes to cells from both types of
dogs (Figure 4) we were able to conclude that ATR-induced
AP changes do contribute significantly to Ca2 release and
contractile disturbances but that APD alterations account for
only a minority of the abnormalities observed. We identified
a range of additional contributors, indicating that the contrac-
tile dysfunction caused by ATR is multifactorial and imply-
ing that the targeting of any single pathophysiological com-
ponent is unlikely to be successful. Indeed, despite the fact
that the repolarization-prolonging agent AVE0118 was the
most effective single intervention in restoring atrial contrac-
tility in AF remodeled goats,3 atrial shortening velocity
abnormalities were incompletely reversed (by 65% in RA and
75% in left atrium), whereas AERP was increased to 120% of
pre-AF values.
ATR can cause APD abbreviation by several ionic mech-
anisms, including ICaL reduction and increased inward recti-
fier currents.21,27 The present study is the first to address the
specific role of ICaL reduction, independent of associated
APD decreases, in ATR-induced Ca2 release and contractile
impairments. Our results indicate that ICaL decreases produce
disproportionate impairments by virtue of their combined
effects on APD and Ca2 entry through ICaL channels.
Previous experimental studies of ATR AF-related contrac-
tile dysfunction have used animals with uncontrolled ventric-
ular responses,2,3,7,15 resulting in varying degrees of ventric-
ular dysfunction known to importantly alter atrial
cardiomyocyte subcellular properties and Ca2 handling.13
Here, we show that relatively short-term (7-day) ATR
itself, with a controlled ventricular response and unaltered
ventricular function (Table 2), significantly depresses
atrial contractility through a variety of cellular and sub-
cellular mechanisms.
Potential Limitations
We chose a 1-week period of ATR based on the fact that ion
current changes caused by ATR reach near steady-state after
1 week.4 Shapiro et al28 showed that patients with acute AF
(mean duration, 1.8 days) do not show significant postcar-
dioversion atrial dysfunction, whereas AF lasting longer than
1 week causes substantial atrial contractile abnormalities that
require several days to recover. ATR lasting for considerably
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longer periods could produce further changes in contractility
involving additional mechanisms where the existence of
slowly developing components to AF remodeling is well
recognized.29,30 Nevertheless, the contractility changes that
we observed are quite similar to those noted by Lenaerts et al7
after a mean 129-day AF period in sheep.
Our studies indicate that a variety of mechanisms likely
contribute to ATR-induced Ca2 release and contractile
abnormalities, which is somewhat unsatisfying because the
precise contribution of each individual component is difficult
to assess and may vary with the duration of ATR, presence of
associated heart disease, drug therapy, and so forth. As
unappealing as this biological reality is, it is important to
appreciate that the variety of mechanisms contributing to
atrial contractile dysfunction after as few as 7 days of ATR
suggests that therapies targeting common upstream signaling
events or rapid atrial activation itself may be more effective
than attempting to intervene at the level of specific down-
stream pathophysiological contributors to hypocontractility.
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CLINICAL PERSPECTIVE
Atrial fibrillation diminishes atrial contractility, even after sinus rhythm is restored, potentially contributing to
thrombogenicity. In a canine model, we found that 1 week of 400-bpm atrial tachycardia decreases atrial contractility and
action potential duration. In contrast to prior suggestions, we found that shortening of action potential duration alone is not
sufficient to explain the decrease in contractility. Tachycardia-induced reductions in L-type calcium current independently
reduce calcium transients and cell contraction. Modifications in subcellular calcium handling that impair transmission of
calcium release signals from the cell surface to the contractile apparatus were present. Furthermore, changes in contractile
protein regulation by phosphorylation may impair contractile element function. Thus, rapid atrial tachycardia, as occurs in
atrial fibrillation, impairs atrial contractile function by multiple mechanisms, including, but not limited to, action potential
duration abbreviation. These findings suggest that atrial contractility may be more effectively improved by approaches
directed at common upstream mechanisms rather than modulating action potential duration alone.
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Supplemental Material 
Detailed Materials and Methods 
Animal Model 
Sixty-three adult mongrel dogs (22-36 kg) were divided into two groups:  1) control (CTL, n=35) 
and 2) 1-week atrial tachycardia remodeling (ATR, n=28).  ATR dogs were initially anesthetized 
with diazepam (0.25 mg/kg IV)/ketamine (5.0 mg/kg IV)/halothane (1% to 2%).  Unipolar leads 
were inserted fluoroscopically into the right-ventricular apex (RV) and right-atrial (RA) 
appendage, and connected to separate pacemakers implanted in the neck.  Atrioventricular (AV) 
block was created by radiofrequency-ablation to control ventricular rate during ATR. The RV-
pacemaker was programmed to 80 bpm.  After 24-hour recovery, the atrial pacemaker was 
programmed to pace the RA at 400 bpm for 7 days.  
 On study days the atrial pacemaker was deactivated and an open-chest electrophysiological 
study was performed. Dogs were anaesthetized with morphine (2 mg/kg SC) and α-chloralose 
(120 mg/kg IV, followed by 29.25 mg/kg per hour) and ventilated mechanically.  RA-appendage 
effective refractory periods (ERPs) were determined at basic cycle lengths (BCLs) of 150, 200, 
250, 300 and 360 ms with 8 basic stimuli followed by one premature stimulus (5-ms decrements).  
AF (an irregular atrial rhythm>400 bpm) was induced by burst pacing.  Mean AF duration was 
determined in each dog as an index of the AF-maintaining substrate in that dog.  Mean±SEM AF-
duration was calculated in each experimental group as previously described, based on the average 
individual AF-duration values in each dog.  Hemodynamic data were measured with fluid-filled 
catheters and transducers.  All animal-care and -handling procedures were in accordance to 
National Institutes of Health guidelines, and were reviewed and approved by the Animals 
Research Ethics Committee of The Montreal Heart Institute.   
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Transthoracic Echocardiography 
Transthoracic echocardiography was performed under sedation (Atravet 0.07 mg/kg and 
buprenorphine 0.009 mg/kg IM) with an M3S probe (2.0-4.3 Megaherz) and a Vivid 7 Dimension 
system (GE Healthcare Ultrasound, Horten, Norway).  All recordings were performed in sinus 
rhythm, with atrial tachypacemakers turned off to permit accurate analyses under comparable 
conditions.  To study left-atrial (LA) emptying and contractile function, an apical 4-chamber view 
was obtained, LA area in both cardiac systole (defined as the largest) and cardiac diastole 
(defined as the smallest) was measured.  M-mode echocardiogram was obtained at the aortic-
valve level in the parasternal long axis view to measure LA-diameters.  Atrial fractional 
shortening was calculated as (systolic area-diastolic area)/systolic area×100% for area; and 
(systolic diameter-diastolic diameter)/systolic diameter×100% for diameter.  Pulsed-wave 
Doppler was used to study transmitral flow in the apical 4-chamber view.  Peak velocity in early 
filling e-wave, and atrial filling a-wave (following a sinus p wave between two QRS deflections 
on a simultaneously-recorded ECG) were obtained, and e/a-ratio was calculated.  The average of 
three to six cardiac cycles was used for each and all measurements, with the operator blinded to 
treatment assignment. 
 
Cardiomyocyte Isolation and Frozen-Tissue Samples 
After open-chest studies, hearts and adjacent lung tissues were excised through a median 
thoracotomy and immersed in oxygenated Tyrode solution at room temperature.  RA-tissue from 
n=10 ATR and n=14 control dogs was dissected and immediately frozen in liquid nitrogen for 
molecular biology experiments.  For cellular studies, RA preparations were dissected from n=21 
control and n=18 ATR dogs and afterwards coronary-perfused at ~10 mL/min for cardiomyocyte 
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isolation as previously-described (Qi et al, 2008).  Perfusion was performed with Ca2+-free 
Tyrode solution containing collagenase (110 U/mL CLS II collagenase; Worthington Biochemical, 
Lakewood, NJ) and 0.1% bovine serum albumin for ~40 min, following which single cells were 
obtained by trituration.  
 
Cellular shortening  
Isolated cardiomyocytes were field-stimulated via 10-ms 1.5×threshold square-wave pulses at a 
temperature of 35°C.  Cell-shortening was measured with a video edge-detector, with 
edge-detection cursors positioned at both cell-ends to measure whole-cell shortening.  Cell-
shortening data was calculated based on the average of 10 consecutive beats.  Additionally, we 
analyzed cell-length changes as a function of time by calculating the maximum contracting 
(+ΔL/Δt) and relaxing (-ΔL/Δt) slopes of the cell-shortening curve. 
In AP-clamp experiments, attachment of the patch pipette to the center of atrial cells often 
affected motion of the cell center, which very often resulted in non-linear contraction of one cell 
edge with preserved motion of the other edge. Because of this phenomenon, cellular shortening 
measurements in AP-clamp experiments were always based on absolute shortening of the 
normally-moving cell edge (in µm). 
 
Ca2+-fluorescence Measurements 
[Ca2+]i-transients were recorded with microfluorimetry.  Fluorescence measurements were 
performed with Indo-1AM.  After an incubation period of 4 min with 5-µmol/l Indo-1 AM, cells 
were superfused at 35°C with Tyrode solution (1.8 mmol/L Ca2+) for 20 min.  Cells were excited 
with ultraviolet light (340 nm), while emission was detected at 400 nm and 500 nm with two 
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separate photomultiplier tubes through a 10-μm aperture focused on the cardiomyocyte.  
Emission ratios (400 nm/500 nm, R400/500) were calculated and used to determine [Ca2+i]. 
 Ratiometric Ca2+i-measurements were converted into intracellular Ca2+-concentration 
([Ca2+]i) according to Grynkiewicz et al with the formula [Ca2+]i= Kd×β×(R400/500-Rmin)/(Rmax-
R400/500) as previously described (Qi et al, 2009).  Sarcoplasmic reticulum (SR) Ca2+-content was 
assessed based on the response to 10-second 10-mmol/L caffeine application via a rapid-
perfusion system.  The decay time-constant (τ) was calculated based on a monoexponential fit to 
the [Ca2+]i-decay curve. 
Isolated cardiomyocytes from additional control and ATR-dogs were also studied by 
confocal microscopy to analyze subcellular Ca2+-transient properties.  Atrial cardiomyocytes 
were incubated with the Ca2+-indicator Fluo-4-AM and placed in a perfusion chamber.  Confocal 
microscopy was performed with an inverted microscope (Olympus IX 81, Olympus Canada, 
Markham, Ontario) equipped with a confocal laser line-scanning unit (Olympus Fluoview FV 
1000).  Ca2+-transients were recorded under steady state field stimulation at 1 Hz.  Line-scanning 
was performed with an optical resolution of 512×512 pixels and a temporal resolution of 1.8-2.0 
ms/line.  For longitudinal cell-scanning the lines were placed in the middle of the cell in a 
longitudinal direction; for transverse scans, lines were positioned at a 90° angle to the 
longitudinal cell axis, avoiding the nucleus.  In addition z-scans were performed to confirm a 
central position in the z-axis.  Analysis was performed with Fluoview analysis software (FV10-
ASW 2.0, Olympus Canada).  For longitudinal scans, three regions of interest (width 10 µm) 
were placed over the left lateral, right lateral, and over the central part of the cell (see Online-
Figure 8A and C) to determine subcellular Ca2+-transients.  For transverse scans, 2 regions of 
interest (width 2 µm) were placed over the subsarcolemmal (SSL) and central part of the cell (see 
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Figure 5A and B).  For mean-data analysis, 5 consecutive beats of each region of interest were 
averaged per cell and afterwards per dog, allowing a comparison of lateral (longitudinal scans) or 
subsarcolemmal (transverse scans) to central Ca2+-transient amplitudes.  Fluorescence intensity 
values (F) were normalized to the minimal end-diastolic fluorescence intensity (F0) in each region 
of interest, resulting in F/F0 ratios. Ca2+-transient values are represented as Δ F/F0 indicating 
(Fmax- F0)/ F0. 
 
T-tubule network analysis: 
Freshly isolated atrial cells from CTL dogs (n=3) and ATR dogs (n=3) were plated on laminin 
(Sigma) coated glass-bottomed Petri dishes (Fluorodishes, World Precision Instruments, Sarasota, 
FL). Cells were labeled with 2 μmol/L of the membrane marker di-4-ANEPPS (Invitrogen, 
Burlington, ON) diluted in Tyrode solution. Image acquisition started 2 minutes post-staining and 
never lasted more than 15 minutes to prevent di-4-ANEPPS intracellular accumulation. Samples 
were excited with an argon (488-nm) laser and emitted fluorescence over 515-nm Z-series (250 
nm) was acquired with an LSM 710 confocal microscope (Carl Zeiss, Toronto, ON) using an LD 
LCI Plan-Apochromat 25×/0.8 Imm. Korr DIC set for water immersion. The calculated point 
spread function (cPSF) of the imaging system was obtained using 170-nm diameter fluorescent 
latex beads (Invitrogen) imaged at an x-y resolution of 41 nm and vertical z stacks of 250 nm 
separation. Experiments were carried out at 37ºC. Acquired z-series were deconvolved using 
maximum likelihood estimation with a Richardson-Lucy algorithm following Gaussian pre-
filtering implemented with Huygens Professional 3.5.0; Scientific Volume Imaging, Hilversum, 
Netherlands (van Kempen et al, 1996). The z-sections were further iso-sampled (Huygens Pro, 
SVI) in order to make the z-spacing the same as the x-y. In each case, the distance to the surface 
 at Vrije on July 11, 2011circep.ahajournals.orgDownloaded from 
6 
sarcolemmal membrane was determined to crop 2-μm thickness z-central sections avoiding the 
top and bottom surfaces. Any fluorescent objects outside the cell were removed by editing images 
with Zen software (Carl Zeiss). Cropped sections were rendered as Maximum Intensity 
Projections. Resulting projections were analyzed by excluding the cell membrane and quantifying 
intracellular membrane staining. The inner face of cardiomyocyte sarcolemmal membranes was 
used to determine the contour of the intracellular space within the projections. The surface of the 
resulting intracellular region was then determined and the mean pixel intensity calculated. T-
tubule density was estimated from the mean pixel intensity normalized to the surface area of the 
intracellular region for each cardiomyocyte.    
 
Cellular Electrophysiology 
Action-potential (AP) recordings were performed with whole-cell perforated-patch technique and 
current-clamp mode.  Tip resistances were between 3 and 5 MΩ.  Pipette tips were filled with 
nystatin-free intracellular solution by capillary action, and pipettes were then back-filled with 
nystatin-containing (600-µg/ml) pipette solution.  Average junction potentials were 15.9 mV and 
were corrected for AP-recordings only.  All recordings were performed at 35±0.5°C.   
 Normal Tyrode solution contained (mmol/L):  NaCl 136, KCl 5.4, MgCl2 1, CaCl2 1.8, 
NaH2PO4 0.33, HEPES 5 and dextrose 10 (pH 7.4, NaOH).  The pipette solution for AP-
recording contained (mmol/L) GTP 0.1, K+-aspartate 110, KCl 20, MgCl2 1, ATP-Mg 5, HEPES 
10, Na2-phosphocreatine 5, and EGTA 0.05, pH 7.4 (KOH).   
For L-Type Ca2+ current (ICa,L) measurement the extracellular solution contained (in 
mmol/L) tetraethylammonium chloride 136, CsCl 5.4, MgCl2 1, CaCl2 2, NaH2PO4 0.33, dextrose 
10, and HEPES 5, titrated to pH 7.4 with CsOH. Niflumic acid (50-μmol/L) was added to inhibit 
Ca2+-dependent Cl--current, and 4-aminopyridine (2-mmol/L) was added to suppress Ito.  The 
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pipette solution for ICa,L-recording contained (mmol/L) CsCl 120, tetraethylammonium chloride 
20, MgCl2 1, EGTA 10, MgATP 5, HEPES 10, and Li-GTP 0.1, titrated to pH 7.4 with CsOH.  
For separate experiments evaluating the contribution of Ca2+-dependent ICa,L inactivation to ICa,L 
measurements in control and ATR cells, EGTA was withdrawn from the pipette solution to 
exclude EGTA-related Ca2+ buffering effects. 
 AP voltage-clamp (whole-cell perforated patch) was used to evaluate AP-dependent effects 
on Ca2+ transients and cell shortening.  RA-cardiomyocytes were subjected to typical AP-
waveforms from control and ATR cardiomyocytes at 2 Hz for sequential 6-min periods (in 
randomized order).  Parallel Ca2+ transients (10-20 beats) were recorded in 120-s intervals.  For 
analysis all Ca2+-transients obtained during the 6-min periods were averaged and mean±SEM 
were calculated within each AP-waveform group.  
 
Force Measurements in Single Skinned Cardiomyocytes 
Cardiomyocytes were mechanically isolated, permeabilized and mounted in the experimental set-
up as described previously (Van der Velden et al, 2003).  Isometric force measurements were 
performed at 15°C and a resting sarcomere length of 2.2 μm.  The rate of force redevelopment 
was determined during activation at different Ca2+-concentrations when the steady isometric 
force level was reached, by rapidly (<1 ms) shortening the myocyte by 20% and, after a delay of 
30 ms, restretching it to the original length (Lo).  Force redevelopment after the restretch was 
fitted to a single exponential  (Marquart-Levenberg algorithm, Kaleidograph, Synergy Software, 
Reading, PA) to estimate the rate of force redevelopment (KTR).  Passive force (Fpassive) was 
determined in relaxing solution by applying the same shortening (20% of Lo) followed by a 
restretch after 10 s. 
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Western Blot and Phosphatase-activity Measurements 
RA-tissue homogenates were prepared from freeze-dried tissue and protein concentrations 
determined with Amido-Black 10B.  Protein-expression was quantified as previously described 
(El-Armouche et al, 2006).  Proteins were fractionated on SDS-polyacrylamide gels and 
transferred to nitrocellulose membranes (BioTrace®NT, Life Sciences, Pall Corporation, Port 
Washington, NY).  Western blotting was performed with primary antibodies to GAPDH 
(1:100000; HyTest, Turku, Finland), calsequestrin (1:2500; Dianova, Hamburg, Germany), 
troponin-I (Tn-I, 1:30000; Chemicon, Millipore, Billerica, MA), Ser23/24 phosphorylated Tn-I 
(1:5000; Cell Signaling, City, State), troponin-C (monoclonal; 1:1000; Fitzgerald, North Acton, 
MA), phosphorylated myosin-light-chain-2a (MLC2a, 1:10000; kind gift from Dr Thomas 
Eschenhagen, University of Hamburg, Hamburg, Germany), SR Ca2+-ATPase (SERCA2a, 1:2000; 
Santa Cruz, Santa Cruz, CA), Thr-287 phosphorylated Ca2+-calmodulin protein kinase-II 
(CaMKII) (1:5000; Promega, Madison, WI), CaMKIIδ (1:200; Santa Cruz), catalytic protein-
kinase A (PKA)-subunit (1:1000, BD Transduction Laboratories, Mississauga, Canada), 
regulatory PKA IIα-subunit (1:500, Santa Cruz), total phospholamban, Ser-16 and Thr-17 
phosphorylated phospholamban (all 1:5000; Badrilla, Leeds, UK), protein phosphatase 1α (PP1α, 
1:500; Biomol, Hamburg, Germany), protein phosphatase 2A (PP2A, 1:2000, affinity purified; 
Upstate Biotechnology, Millipore), Na+/Ca2+-exchanger (NCX1, 1:1000; Affinity BioReagents, 
Thermo Scientific, Waltham, MA), total myosin-binding protein C (MyBP-C, 1:5000), and Ser-
282 phosphorylated MyBP-C (1:1000; kind gifts from Dr Lucie Carrier, University of Hamburg, 
Hamburg, Germany), total ryanodine receptor (RyR2), and Ser-2809 and Ser-2815 
phosphorylated RyR2 (1:5000, 1:5000 and 1:2500, respectively; kind gifts from Dr Andrew 
Marks, Columbia University, New York, NY).  Detection was performed with suitable secondary 
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antibodies and protein bands were visualized with electrochemoluminescence reagents (Thermo 
Scientific) and Hyperfilm-ECL (GE Healthcare, Little Chalfont, UK).  The films were evaluated 
densitometrically with Phoretix 1D software (Biostep, Jahnsdorf, Germany).  Atrial homogenates 
were used to measure phosphatase-activity.  Serine/threonine protein-phosphatase activity was 
assessed with phosphorylase-A as substrate, and quantified as nanomoles of 32Pi released per 
milligram protein/minute.  Differentiation between PP1 and PP2A activities measurements was 
obtained with okadaic acid (3 nmol/L). 
 
Myosin heavy chain and titin isoforms 
The myosin heavy chain isoform (MHC) composition was analyzed by one-dimensional SDS 
polyacrylamide gel electrophoresis (SDS-PAGE) according to previously-described methods 
(Neagoe et al, 2002; Warren et al, 2003).  The separating gel contained 12% total acrylamide 
(acrylamide to bis-acrylamide ratio 200:1; pH 9.3), while the stacking gel contained 3.5% total 
acrylamide (acrylamide to bis-acrylamide ratio 20:1; pH 6.8).  Gels were silver-stained and 
analyzed by laser densitometry.  To check for linearity, different amounts of protein were loaded 
on the gels and the density of the MHC bands was determined.  Only samples within the linear 
range (typically 0.2-1.0 μg of total  protein) were used in the evaluation.  
Dog atria were homogenized in modified Laemmli buffer and agarose-strengthened 2% 
SDS-PAGE to detect titin was performed as described (Neagoe et al, 2002; Opitz et al, 2004).  
Protein-bands were visualized with Imperial protein stain, scanned, and analyzed 
densitometrically.  Average titin isoform composition was calculated from 10 measurements per 
experimental condition. 
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Data Analysis 
The force-pCa relation was fit by a non-linear procedure to the Hill equation: 
F(Ca2+)/Fmax = [Ca2+]nH/(Ca50nH+[Ca2+]nH), where F is steady-state force at different Ca2+ 
concentrations.  Fmax denotes the active steady isometric force component developed at saturating 
Ca2+-concentration.  The Hill coefficient (nH) is a measure of the steepness of the relationship, 
and Ca50 (or pCa50) represents the Ca2+ concentration at which tension= 0.5×Fmax, i.e. the mid-
point of the relation.  
All data are presented as mean±SEM.  For single comparisons paired or non-paired t-tests 
were applied as appropriate.  Repeated-measures analyses were performed with two-way 
ANOVA.  When significant interactions were found between main-effects, Bonferroni-corrected 
t-tests were applied to determine the levels of the repeated measure at which significant 
differences occurred (the P-values shown were obtained by multiplying each P by the number of 
repeated tests performed). In the absence of interaction, the significance of main-effect 
differences is shown. Analyses of non-repeated measurements in multiple groups (control versus 
24-hour recovery versus 48-hour recovery) were performed by one-way ANOVA, followed (if 
significant) by least-significant difference test. The specific statistical test applied for each 
analysis follows: 
 
• Figures 1C, D, E: non-paired t-tests.  
• Figures 2B, C :  non-paired t-tests.  
• Figure 2E : 2-way ANOVA for repeated measures; main effect factors: group (CTL vs 
ATR), frequency; significant group effect for CTL vs ATR; no significant interaction.  
• Figures 3 B, C: non-paired t-tests.  
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• Figure 3E: 2-way ANOVA for repeated measures; main effect factors: group (CTL vs 
ATR), frequency; significant group effect for CTL vs ATR; no significant interaction.  
• Figure 3F: 2-way ANOVA; main effect factors: group (CTL vs ATR), test potential (TP); 
significant interaction between TP and group, individual P-values at each TP by 
Bonferroni-corrected t-test (corrected values are shown).  
• Figures 4B, C, E, F: paired t-tests (each set of observations was based on repeated 
measures under each condition in each cell).  
• Figure 5B: 1-way ANOVA, individual P-values by least significant difference test.  
• Figure 6: non-paired t-tests.  
• Figure 7: non-paired t-tests.  
• Figure 8: non-paired t-tests. 
 
• Tables 1 and 2: non-paired t-tests. 
• Table 3: 1-way ANOVA, individual P-values by least significant difference test.  
 
• On-line Figure I : 2-way ANOVA for repeated measures; main effect factors: group (CTL 
vs ATR), frequency; significant group effect for CTL vs ATR; no significant interaction.  
• On-line Figure II : 2-way ANOVA for repeated measures; main effect factors group (CTL 
vs ATR), frequency; no significant group effects or interaction.  
• On-line Figure III : 2-way ANOVA for repeated measures; main effect factors group (CTL 
vs ATR), test potential (panels A-C), P1-P2 interval (D); no significant group effects or 
interaction.  
• On-line Fig IVB : 2-way ANOVA for repeated measures; main effect factors group (CTL 
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vs ATR), test potential; significant interaction between group and test potential; individual 
P-values at different test potentials by Bonferroni-corrected t-test (corrected values are 
shown).  
• On-line Figures VA and B: 2-way ANOVA for repeated measures; main effect factors 
group (CTL vs ATR), test potential; panel A: no significant interaction, significant main 
effect for group is shown. No significant interaction or main effect in panel B. 
• On-line Figure VC: Non-paired t-tests for group (control vs ATR) activation and 
inactivation V1/2 values shown in insets.  
• On-line Figure VD: non-paired t-test on time constants shown in inset.  
• On-line Figure VI: non-paired t-tests.  
• On-line Figure VII : 2-way ANOVA for repeated measures; main effect factors group 
(CTL vs ATR), frequency; significant group effect for group (CTL vs ATR); no significant 
interaction.  
• On-line Figure VIII: non-paired t-tests.  
• On-line Figure IX: illustrates raw data from one sample from each group, results for mean 
data mentioned in text are compared by non-paired t-test.  
• On-line Figure X: non-paired t-tests.  
• On-line Figure XIA : 2-way ANOVA for repeated measures; main effect factors group 
(CTL vs ATR), frequency; significant group effect for group (CTL vs ATR); no significant 
interaction.  
• On-line Figures XIB, XIC: 1-way ANOVA with least significant difference test. 
 
A 2-tailed P<0.05 was considered statistically-significant.  The authors had full access to 
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the data and take responsibility for its integrity.  All authors have read and agree to the 
manuscript as written. 
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Online Figure 1. Relative cell shortening control (CTL) vs. ATR frequency 
dependence.  Mean±SEM relative cell shortening as function of stimulation frequency 
(n=11 cells for CTL, n=14 cells for ATR, ***P<0.001 ATR vs. CTL, effect of group). 
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Online Figure 2. Ca2+-transient diastolic levels ATR vs. control (CTL) frequency dependence. 
Mean±SEM Ca2+-transient diastolic levels in CTL and ATR cardiomyocytes as function of 
stimulation frequency (n=25, n=15 cells for CTL, ATR; P=NS ATR vs. CTL).
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Online Figure 3. Measurements of ICaL with EGTA-containing pipette solution. A,B, ICaL inactivation with EGTA-containing pipette 
solution; means±SEM, ICaL inactivation time constants tau-fast (A) and tau-slow (B) in control (CTL) and ATR (n=10 cells in CTL, n=16 
cells in ATR; *P<0.05, **P<0.01, ATR vs. CTL). C, voltage dependence of ICaL inactivation and activation. Curves are Boltzmann fits to the 
mean data, insets show corresponding V1/2 for inactivation (left) and activation (right). D, ICaL time-dependent recovery; monoexponential 
fits corresponding to mean data are shown, inset shows time-dependent recovery time-constants.
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Online Figure 4. EGTA-free measurements of ICaL . A, ICaL recordings at 0.1 Hz in control (CTL) and ATR 
cardiomyocytes with EGTA-free pipette solution; B, Mean±SEM ICaL density in CTL and ATR (n=16 cells/group; 
*P<0.05, ***P<0.001, ATR vs. CTL at same test potential). 
 at V
rije on July 11, 2011
circep.ahajournals.org
D
ow
nloaded from
 
A BFast tau
-20 -10 0 10 20 30 40 50
0
5
10
15
20
25
CTL (n=10) 
ATR (n=16) 
Test potential (mV) 
T
i
m
e
 
c
o
n
s
t
a
n
t
 
(
m
s
)
 
-20 -10 0 10 20 30 40 50
0
30
60
90
120
150
CTL (n=10) 
ATR (n=16) 
Test potential (mV) 
T
i
m
e
 
c
o
n
s
t
a
n
t
 
(
m
s
)
 
C D -80 mV
+10 mV
300 ms 300 ms
0
20
40
60
80
T
i
m
e
 
c
o
n
s
t
a
n
t
 
(
m
s
)
 
CTL (n= 10-16) 
ATR (n= 11-16) 0 100 200 300 400 500
0.0
0.3
0.6
0.9
1.2CTL
ATR
P1-P2 Interval (ms) 
I
2
/
I
1
Test Potential (mV) 
-80 mV
+10 mV
-25
-20
-15
-10
-5
0
-10.0
-7.5
-5.0
-2.5
0.0
V
o
l
t
a
g
e
 
(
m
V
)
 
V
o
l
t
a
g
e
 
(
m
V
)
 
N
o
r
m
a
l
i
z
e
d
c
u
r
r
e
n
t
-120 -80 -40 0 40
0.0
0.3
0.6
0.9
1.2
**
Online Figure 5. A,B, ICaL inactivation with EGTA-free pipette solution; mean±SEM, ICaL inactivation time constants tau-fast (A) and tau-slow (B) in 
control (CTL) and ATR (n=10 cells in CTL, n=16 cells in ATR; ***P<0.001, main-effect of ATR vs. CTL). C, voltage dependence of ICaL inactivation 
and activation. Curves are Boltzmann fits to the mean data, insets show corresponding V1/2 for inactivation (left) and activation (right). D, ICaL time- 
dependent recovery; monoexponential fits corresponding to mean data are shown, inset: recovery time-constants, **P<0.01.
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Online Figure 6. A, Top: Immunoblots of total RyR2, Ser2809-P RyR2 and Ser2815-P RyR2, calsequestrin2 (CSQ2) and GAPDH.  Bottom: Mean±SEM protein-band 
intensities of total RyR2, Ser2809-P RyR2 and Ser2815-P RyR2 relative to control (CTL), and CSQ2 normalized to GAPDH, expressed relative to CTL.  (n=10 CTL and 7- 
9 ATR atria for RyR2, and n=14 CTL and 10 ATR for CSQ2; P=NS ATR versus CTL). B, Top: Immunoblots of NCX1, SERCA2a, total PLB, Ser16-P PLB and Thr17-P PLB 
and GAPDH.  Bottom: Mean±SEM protein-band intensities normalized to GAPDH, relative to control.  (n=10 CTL and n=8 ATR atria for NCX1, n=14 CTL and 10 ATR atria/for 
SERCA and PLB/-P analysis, P=NS ATR vs. CTL). 
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Online Figure 7.
 
Longitudinal spread of Ca2+-fluorescence in control (CTL) and 
ATR cells. Confocal subcellular Ca2+-transient analysis: A, B; representative 
images showing the cardiomyocyte (left) with the line scan over time (middle) of a 
control (CTL, A) and ATR (B) cell; rectangular boxes indicate the regions of 
interest in the right lateral, central and left lateral part of the cell; the 
corresponding superimposed Ca2+-transient recordings of each region of interest 
are shown in the right insets. C,
 
Corresponding mean±SEM data for ATR vs. 
control Ca2+-transient amplitudes in the left lateral, central and right lateral part of 
the cell (n= 5 dogs/group, *** P<0.001 for factor group, ATR vs. control; not 
significant for factor location; no interaction between the 2 factors).
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Online Figure 8.
 
A, Examples of di-4-ANEPPS staining in control (CTL) and ATR cardiomyocytes, in 
longitudinal (left) and transverse (right) views. B,
 
T-tubule density calculated by image analysis of non- 
membrane di-4-ANEPPS staining. **P<0.01.
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Examples of one- 
dimensional SDS-PAGE gels of control (CTL) 
and ATR samples determining contractile 
protein composition.
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Online Figure 10.      A,
 
Protein-phosphatase (PP)-activity 
normalized to control (CTL, n=10 atria per group/analysis, *P<0.05 vs 
CTL) and B, Corresponding protein-expression. Representative 
examples (top) and mean±SEM protein-band intensities (bottom).  
(n=14 CTL /10 ATR for PP1, n=10 CTL/ 8 ATR for PP2A 
atria/analysis; P=NS ATR vs CTL).  C, Right: Representative 
immunoblots. PKAII
 
bands are at 51 and 54 kDa, quantified as sum 
of the bands.  Left: Mean±SEM protein band-intensities. (n=10 CTL, 
8 ATR atria/analysis, *P<0.05 versus CTL). D, Right:
 
Immunoblots of 
total CaMKII, Thr-287-phosphorylated CaMKII (autophosphorylated) 
and GAPDH.  Top bands (58 kDa) represent CaMKIIB, bottom 
(56 kDa) CaMKIIC.  Left:
 
Mean±SEM protein-band intensities.  
(n=16 CTL, 8 ATR atria/analysis, *P<0.05 vs CTL). All protein band- 
intensities are normalized to GAPDH and expressed relative to CTL.Online Figure  10
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Online Figure 11. Recovery time 
course of electrophysiological and 
contractile properties; A
 
, 
Mean±SEM APD90 at different 
frequencies (**P<0.01, ATR REC 
24 h versus CTL, and P=NS for 
ATR REC 48 h versus CTL, effect 
of group). B, Mean±SEM Ca2+- 
transient amplitude, **P<0.01 ATR 
REC 24 h versus CTL, P=NS for 
ATR REC 48h versus CTL. C, 
Mean±SEM relative cell shortening, 
***P<0.001 ATR REC 24h versus 
CTL, P=NS for ATR REC 48h 
versus CTL. CTL=control, 
REC=recovery.
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